Pembrolizumab Survival Data: Minority Of Patients Are Sur...

Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had
Annual Meeting Photo

Annual Meeting
3 ปี 104 Views
ประเภท:
ลักษณะ:
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had.